Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts ...

Three years after President Joe Biden signed the Inflation Reduction Act, the Trump administration has significantly reduced the former president's key bill.

The drug industry’s top lobbying group is appealing its latest loss in its challenge to Medicare’s Drug Price Negotiation ...

The Inflation Reduction Act (IRA) authorized the federal government to force prescription drug manufacturers to "negotiate" drug prices for ...

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, ...

On August 1, 2025, the Health Resources and Services Administration (HRSA), administrator of the 340B Drug Pricing Program, announced its voluntary 340B Rebate Model Pilot Program in a Notice and set ...

A voluntary rebate pilot for the 340B drug discount program is drawing attention as a potential way to address concerns over ...

The "Big Beautiful Bill" could lead to 11.8 million fewer Medicaid enrollees over the next decade. The U.S. healthcare system ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a ...

New York hospitals that get discounted drugs through a controversial federal program are gearing up for a new pilot that they ...

While costs for post-employment benefits continue to rise, assets set aside to fund these obligations remain low.

Vermont regulators also grilled executives from the hospital network and UVM Medical Center about revenue overages, profit margins, and lowering charges to commercial insurance during an annual budget ...